Venous Thromboembolism
Conference Coverage
Phase 3 data support apixaban for cancer-associated VTE
The rate of major bleeding was similar with apixaban and dalteparin.
Conference Coverage
Tofacitinib and TNF inhibitors show similar VTE rates
A review of more than 50,000 U.S. rheumatoid arthritis patients shows similar venous thromboembolism rates with tofacitinib and TNF inhibition.
From the Journals
All patients with VTE have a high risk of recurrence
Researchers suggest rethinking categorization of patients with incident venous thromboembolism.
Conference Coverage
EHR-guided strategy reduces postop VTE events
BOSTON – Missed doses of enoxaparin correlate with increased incidence of deep vein thrombosis.
News
Rivaroxaban gains indication for prevention of major cardiovascular events in CAD/PAD
Rivaroxaban (Xarelto) is the first direct oral anticoagulant to gain an indication for prevention of cardiovascular events.
Conference Coverage
Obesity paradox extends to PE patients
SAN ANTONIO – The obese patients in the analysis had a lower mortality risk, despite receiving more thrombolytics.
Conference Coverage
A new, simple, inexpensive DVT diagnostic aid
NEW ORLEANS – The CBC holds info that outperforms the D-dimer test.
Conference Coverage
VTE risk after bariatric surgery should be assessed
SEATTLE – Thromboelastometry can play a role in identifying bariatric surgery patients at risk for VTE.
Conference Coverage
The ‘holy grail’ of thrombosis prevention
SAN DIEGO – One expert says it’s the ability to determine the risk of recurrence with or without continuation of anticoagulant treatment.